Multiple Myeloma; BCL-2; Apoptosis; BH3 mimetics; BH3 profiling Despite a significant improvement in the survival of patients with multiple myeloma (MM), the disease remains incurable and innovative strategies are needed. Interactions among BCL-2 family proteins mainly determines cellular fate decision in response to drug therapy. Thus, anti-apoptotic members such as BCL-2, BCL-X L or MCL-1, represent an attractive target for therapy 1 . BH3 profiling is a functional assay that identifies the tumor cell's addiction to these anti-apoptotic members 2 . Figure 1a 2 , 5 , 6 . The release of cytochrome c induced by each peptide was quantified by FACS analysis. Dependence on individual anti-apoptotic proteins was found to be very heterogeneous from one cell line to another (Figure 1b) . One cell line (LP-1) was found to be relatively purely MCL-1 dependent. XG-5 and SKMM2 were found to be relatively BCL-2 dependent and MM1-S was found to be relatively purely BCL-X L dependent. The remaining cell lines were characterized by co-dependency on anti-apoptotic proteins: BCL-2 and BCL-X L (KMS12-PE) or BCL-X L and MCL-1 (NCI-H929 and RPMI-8226) and BCL-2 and MCL-1 (L-363). We then determined the in vitro sensitivity of MM cell lines to the BH3 mimetics ABT-199 and ABT-263 (Figure 1c) . The mitochondrial response to BAD peptide predicted the in vitro sensitivity to ABT-263 (Figure 1d ). The BAD minus HRK mitochondrial response was used to reflect the specific BCL-2 dependency and significantly predicted sensitivity to ABT-199. (Figure 1d ) Finally, the cytochrome c release in response to ABT-199 and ABT-263 strongly correlated with the in vitro sensitivity to the drug.
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We then determined the mitochondrial priming of primary plasma cells obtained from 14 different patients with a diagnosis of de novo or relapsed MM. Patient characteristics are summarized in Figure 2a . As observed with cell lines, patient samples showed a heterogeneous dependence on anti-apoptotic proteins ( Figure 2a ). Of note, mitochondria of 5 patient samples were found to be relatively independent of BCL-2, BCL-X L or MCL-1. We also determined the in vitro sensitivity to ABT-199 and ABT-263. Three and 5 samples were found sensitive (LD 50 ≤ 100 nM) to ABT-199 and ABT-263, respectively. As shown in Figure 2b , BH3 profiling using the BAD peptide correlated with in vitro sensitivity to ABT-199 and 263.
BH3 profiling is a unique, functional method to measure the dependence to the antiapoptotic proteins in live cancer cells. The present study demonstrates that Multiple Myeloma is a heterogeneous disease regarding its dependence on anti-apoptotic proteins and cannot be considered as monolithically BCL-2, BCL-X L or MCL-1 dependent. MCL-1 is expressed in MM cells at levels higher than normal plasma cells and its expression level has been shown to affect clinical outcome 7 , 8 . Here, mitochondria from half of MM cell lines (4/8) and from almost one third of primary samples (4/14) were found to be MCL-1 dependent. These results are consistent with the requirement for MCL-1 for survival of many myeloma cells. BH3 profiling also identified a subset of BCL-2 and/or BCL-X L dependent MM cells with relatively less dependence on MCL-1 and correctly predicted sensitivity to the BH3 mimetics ABT-199 and 263. In our series, one MM cell line (MM1-S) and 2 primary samples (#7 and #11) were found to be sensitive to ABT-263 but insensitive to , that linked to their BCL-X L dependence determined using BH3 profiling. Even if these findings indicate that BCL-X L could be an attractive target for MM, the BCL-X Lrelated platelet toxicity has impaired the clinical development of ABT-263 9 . Previous studies identified MM cells sensitive to BH3 mimetics based on their BCL-2/MCL-1 mRNA ratio 10 , 11 or interactions of BCL-X L and BCL-2 with BIM 12 . From a practical point of view, BH3 profiling can be performed in just a three hours with fewer cells (5.10 4 plasma cells to determine response to the BAD BH3 peptide). This consideration is of importance because bone marrow samples from MM patients usually contain a low percentage of plasma cells (the median percentage of plasma cell in BM aspirate was 9% in our series). It has been previously reported that sensitivity to ABT-199 was restricted in MM patients with t(11;14) translocation 11 . Here, among the three ABT-199 sensitive samples, two were found to be t (11;14) . By including previous data from Touzeau et al. 11 , sensitivity to ABT-199 from 29 different primary MM samples was analyzed. Overall, 7 samples (24%) were found to be sensitive to the drug (LD 50 <100 nM). Interestingly, 6 of these ABT-199 sensitive samples carried the t(11;14) translocation. Of note, the remaining sensitive sample was found to be BCL-2 dependent according to BH3 profiling. Moreover, one sensitive patient sample was found to be negative for the t(11;14) translocation suggesting that BCL-2 dependence may exist beyond this cytogenetic subgroup. The positive (PPV) and negative (NPV) predictive value of BH3 profiling to predict ABT-199 sensitivity were 75 and 100%, respectively (supplemental Table) .
Overall, and as previously demonstrated in other hematologic malignancies 2 , 13 , 14 , BH3
profiling identifies BCL-2 dependence in myeloma cells and predicts sensitivity to BH3 mimetics. Phase 1 clinical trials evaluating ABT-199 as a single agent (NCT01794520) or in combination with bortezomib plus dexamethasone (NCT01794507) in relapsed MM patients are ongoing. Preliminary results of these trials demonstrated significant anti myeloma response with a favorable safety profile. 16 , 17 The promising predictive value of BH3 profiling needs to be confirmed in the context of prospective clinical studies. Because BCL-2 dependency was found only in a subset of myeloma patients, future clinical trials with an efficacy objective should integrate biomarkers such BH3 profiling to stratify potential candidates for ABT-199 therapy.
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Refer to Web version on PubMed Central for supplementary material. treatment with 0.002% w/v digitonin. BAD, HRK and MS1 peptides sequences have been previously described 7 , 8 . Mitochondria in the permeabilized cells were exposed to peptides for 45 min at 26°C before fixation with 2% formaldehyde at room temperature for 15 min. After addition of neutralizing buffer, cells were stained with anti-cytochrome c-Alexa488 
